Hepatology

Raj Vuppalanchi, MD, explains how liver stiffness is becoming a prognostic tool in PBC and PSC, and why context matters when interpreting the number.

Post hoc phase 2 data show survodutide improved MASH and fibrosis endpoints across all weight loss categories, including patients losing less than 5%.

Pavel Strnad, MD, discusses pooled phase 2 data showing fazirsiran cut liver Z-AAT burden by about 90% in AATD liver disease and why screening matters now.

Timucin Taner, MD, PhD, explains how to reduce long-term immunosuppression after liver transplant, who to start with, and why biomarkers remain the gap.

In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.

Zobair Younossi, MD, MPH, discusses MAESTRO-NAFLD-1 data linking resmetirom to improved worry and health distress scores in compensated MASH cirrhosis.

Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.

Quantitative HBsAg testing now determines which patients on antiviral therapy may qualify for bepirovirsen, a finite add-on treatment for chronic hepatitis B.

Marlyn Mayo, MD, discusses long-term seladelpar data linking IL-31 reductions to PBC pruritus improvement and why the cytokine is not ready to guide treatment.

Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.

Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.

Once-monthly efimosfermin alfa reduced liver stiffness, ELF, and PRO-C3 through 52 weeks in MASH with F2–F4 fibrosis, including compensated cirrhosis.

Marlyn Mayo, MD, discusses 4-year ELATIVE data on elafibranor sustaining biochemical response across PBC stages, with stable fibrosis markers.

In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.

In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.

In patients with compensated MASH cirrhosis, Baveno VII and ANTICIPATE-NASH showed moderate agreement with HVPG and underestimated CSPH prevalence.

In the phase 2b VISTAS trial, volixibat improved sleep vs placebo in PSC with cholestatic pruritus, and itch responders saw greater fatigue and sleep gains.

In the phase 3 ELSPIRE trial, 85.3% of patients with PBC and ALP below 1.67× ULN reached ALP normalization on elafibranor at 52 weeks vs 23.3% on placebo.

Real-world data at AASLD 2026 show 37% to 55% of patients with MASH on resmetirom (Rezdiffra) improved liver stiffness by 25% or more at about one year.

In the phase 3 IDEAL trial, 3 in 4 patients with PBC and ALP below 1.67× ULN reached ALP normalization on seladelpar at 52 weeks, compared with 16.1% on placebo.

October 2026 hepatology news includes FDA approval of bepirovirsen for hepatitis B, new ACLF criteria, ACG cirrhosis guidance, and MASH trial data.

Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.

Five liver societies define ACLF as liver failure plus extrahepatic organ dysfunction or failure, with three grades and FDA-informed trial endpoints.

HBsAg testing becomes central to selecting patients for bepirovirsen, a finite hepatitis B therapy given alongside NA treatment.

HBsAg testing becomes central to selecting patients for bepirovirsen, a finite hepatitis B therapy given alongside NA treatment.